X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5932) 5932
Publication (518) 518
Book Review (50) 50
Book Chapter (36) 36
Conference Proceeding (18) 18
Newspaper Article (14) 14
Book / eBook (10) 10
Government Document (4) 4
Paper (2) 2
Data Set (1) 1
Magazine Article (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3319) 3319
index medicus (2868) 2868
platinum (2281) 2281
animals (1927) 1927
female (1602) 1602
cisplatin (1558) 1558
oncology (1432) 1432
cancer (1244) 1244
antineoplastic agents - pharmacology (1114) 1114
chemotherapy (1085) 1085
male (1056) 1056
cell line, tumor (937) 937
biochemistry & molecular biology (935) 935
cisplatin - pharmacology (783) 783
platinum - chemistry (758) 758
pharmacology & pharmacy (752) 752
middle aged (703) 703
mice (668) 668
antineoplastic agents - chemistry (620) 620
aged (583) 583
apoptosis (569) 569
adult (556) 556
dna (550) 550
dna - metabolism (546) 546
platinum - metabolism (534) 534
rats (534) 534
analysis (532) 532
ovarian cancer (519) 519
antineoplastic agents - therapeutic use (497) 497
organoplatinum compounds - pharmacology (492) 492
ovarian neoplasms - drug therapy (485) 485
cytotoxicity (479) 479
research (475) 475
cisplatin - metabolism (452) 452
chemistry, multidisciplinary (425) 425
platinum complexes (422) 422
electrodes (414) 414
toxicity (401) 401
proteins (397) 397
in-vitro (390) 390
chemistry, inorganic & nuclear (388) 388
tumors (387) 387
antineoplastic agents - metabolism (380) 380
article (372) 372
ligands (369) 369
kinetics (367) 367
apoptosis - drug effects (363) 363
care and treatment (362) 362
chemistry, analytical (360) 360
nanoparticles (360) 360
ovarian neoplasms - metabolism (360) 360
organoplatinum compounds - chemistry (358) 358
cell survival - drug effects (357) 357
cisplatin - administration & dosage (356) 356
resistance (343) 343
drug resistance, neoplasm (339) 339
expression (338) 338
platinum-based chemotherapy (330) 330
cisplatin - pharmacokinetics (328) 328
ovarian neoplasms - pathology (327) 327
prognosis (327) 327
antineoplastic combined chemotherapy protocols - therapeutic use (325) 325
drugs (325) 325
dose-response relationship, drug (320) 320
carboplatin (316) 316
lung neoplasms - drug therapy (314) 314
antineoplastic agents - pharmacokinetics (312) 312
cells (311) 311
binding (306) 306
electrochemistry (306) 306
drug resistance (305) 305
cisplatin - toxicity (303) 303
neoplasms - drug therapy (301) 301
treatment outcome (301) 301
platinum - pharmacology (291) 291
time factors (290) 290
cisplatin - therapeutic use (288) 288
antineoplastic agents (284) 284
tumor cells, cultured (282) 282
dna - chemistry (280) 280
cancer therapies (273) 273
gene expression (271) 271
toxicology (271) 271
carcinoma (263) 263
multidisciplinary sciences (262) 262
cell biology (261) 261
lung cancer (257) 257
dna repair (256) 256
survival (254) 254
cell proliferation - drug effects (251) 251
cis-diamminedichloroplatinum (251) 251
chemistry, medicinal (249) 249
deoxyribonucleic acid--dna (249) 249
dna damage (249) 249
cisplatin - chemistry (248) 248
oxaliplatin (247) 247
antineoplastic agents - administration & dosage (246) 246
complexes (246) 246
organoplatinum compounds - metabolism (246) 246
antimitotic agents (245) 245
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5875) 5875
Japanese (36) 36
Russian (29) 29
Chinese (22) 22
German (13) 13
French (12) 12
Polish (4) 4
Spanish (4) 4
Hungarian (2) 2
Czech (1) 1
Dutch (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e54193
Introduction: Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management of non-small cell lung cancer (NSCLC).... 
OVEREXPRESSION | ARREST | IN-VITRO | DNA | PHARMACOLOGY | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | AGENTS | COPPER | OVARIAN-CANCER | IDENTIFICATION | Proto-Oncogene Proteins c-met - metabolism | DNA Adducts - drug effects | Homeodomain Proteins - metabolism | Humans | Lung Neoplasms - metabolism | Glycoproteins - metabolism | Lung Neoplasms - pathology | Antigens, CD - metabolism | SOXB1 Transcription Factors - metabolism | Dose-Response Relationship, Drug | Flow Cytometry | Peptides - metabolism | Neoplastic Stem Cells - metabolism | Hyaluronan Receptors - metabolism | Biomarkers, Tumor - metabolism | Antineoplastic Agents - pharmacology | Aldehyde Dehydrogenase - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Cell Survival - drug effects | Nanog Homeobox Protein | Carcinoma, Non-Small-Cell Lung - metabolism | Cisplatin - pharmacology | AC133 Antigen | beta Catenin - metabolism | Octamer Transcription Factor-3 - metabolism | Cell Line, Tumor | Cell Proliferation - drug effects | Cell Cycle - drug effects | Drug Resistance, Neoplasm - drug effects | Proteins | Cell death | Analysis | Stem cells | Lung cancer, Small cell | Lung cancer, Non-small cell | Cisplatin | Cell proliferation | Health sciences | Biotechnology | Flow cytometry | Dehydrogenases | Oct-4 protein | Lung cancer | DNA damage | Oncology | Cancer therapies | β-catenin | Signal transduction | Platinum | CD44 antigen | Cell cycle | Deoxyribonucleic acid--DNA | G1 phase | Medical research | Subpopulations | Damage assessment | Cell survival | Markers | Non-small cell lung carcinoma | Tumor cell lines | Survival | Medicine | Hospitals | Molecular modelling | Cell lines | Sensitivity enhancement | DNA adducts | Pluripotency | Tumors | Apoptosis | Cancer | Deoxyribonucleic acid
Journal Article
Cancer, ISSN 0008-543X, 06/2017, Volume 123, Issue S11, pp. 2163 - 2175
Substantial proportions of patients with metastatic melanoma develop brain metastases during the course of their disease, often resulting in significant... 
immunotherapies | targeted therapies | blood‐brain barrier | immune cells | melanoma | brain metastasis | brain parenchyma | blood-brain barrier | COMBINATION THERAPY | OPEN-LABEL | MALIGNANT-MELANOMA | TUMOR-INFILTRATING LYMPHOCYTES | BREAST-CANCER CELLS | STEREOTACTIC RADIOSURGERY | ONCOLOGY | THERAPEUTIC TARGETS | CENTRAL-NERVOUS-SYSTEM | ENDOTHELIAL GROWTH-FACTOR | PHASE-2 TRIAL | Tumor Escape | Transforming Growth Factor beta2 - metabolism | Humans | Glucuronidase - metabolism | Radiosurgery | Extracellular Matrix - metabolism | Antineoplastic Agents - therapeutic use | Vascular Endothelial Growth Factor A - metabolism | Molecular Targeted Therapy | Integrins - metabolism | Brain Neoplasms - metabolism | Receptors, CCR4 - metabolism | Brain Neoplasms - secondary | Immunotherapy | Fibroblast Growth Factor 2 - metabolism | Melanoma - metabolism | Skin Neoplasms - pathology | Cytokines - metabolism | B7-H1 Antigen | Matrix Metalloproteinase 2 - metabolism | Cranial Irradiation | Cell Adhesion | Melanoma - secondary | Skin Neoplasms - metabolism | Brain Neoplasms - therapy | Neovascularization, Pathologic - metabolism | Melanoma - therapy | Blood-Brain Barrier | Medical research | Brain | Therapy | Toxicity | Melanoma | Clinical trials | Pharmacology | Metastasis | Drug development | Chemical compounds | Patients | Morbidity | Metastases | Immune checkpoint | Design improvements | Platinum | Cancer
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 01/2003, Volume 125, Issue 1, pp. 173 - 186
Journal Article
European Urology, ISSN 0302-2838, 2013, Volume 64, Issue 5, pp. 753 - 761
Abstract Background Primary culture and animal and cell-line models of prostate and bladder development have limitations in describing human biology, and novel... 
Urology | MYC (formerly cMYC) | Tissue engineering | Bladder | POU5F1 (formerly OCT4) | KLF4 | SOX2 | Stem cells | Androgen receptor | Pluripotent | NANOG | Ureter | Differentiation | Prostate | Urothelium | INDUCTION | IN-VITRO | DIRECTED DIFFERENTIATION | MESENCHYMAL-EPITHELIAL INTERACTIONS | CULTURE | FIBROBLASTS | UROLOGY & NEPHROLOGY | UROTHELIAL CELLS | EXPRESSION | LINEAGE | HUMAN CANCER | Humans | Middle Aged | Receptors, Androgen - metabolism | Male | Ureter - cytology | Prostate - metabolism | Cellular Reprogramming | SOXB1 Transcription Factors - metabolism | Octamer Transcription Factor-3 - genetics | Cell Differentiation - genetics | Transfection | SOXB1 Transcription Factors - genetics | Time Factors | Gene Expression Regulation, Developmental | Kruppel-Like Transcription Factors - metabolism | Regeneration - genetics | Ureter - physiology | Female | Urinary Bladder - cytology | Prostate-Specific Antigen - metabolism | Prostate - physiology | Ureter - metabolism | Cell Lineage - genetics | Induced Pluripotent Stem Cells - metabolism | Biomarkers - metabolism | Tissue Engineering - methods | Induced Pluripotent Stem Cells - physiology | Urinary Bladder - metabolism | Cell Separation | Cells, Cultured | Uroplakins - metabolism | Proto-Oncogene Proteins c-myc - metabolism | Octamer Transcription Factor-3 - metabolism | Prostate - cytology | Aged | Proto-Oncogene Proteins c-myc - genetics | Kruppel-Like Transcription Factors - genetics | Kallikreins - metabolism | Urinary Bladder - physiology | Embryonic stem cells | Analysis | Platinum Priority – Prostatic Disease
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 11/2016, Volume 124, pp. 380 - 392
Journal Article
Critical Reviews in Oncology and Hematology, ISSN 1040-8428, 2017, Volume 112, pp. 31 - 40
Journal Article
PLoS ONE, ISSN 1932-6203, 2014, Volume 9, Issue 9, pp. e105070 - e105070
Nephrotoxicity is a dose-dependent side effect of cisplatin limiting its clinical usage in the field of cancer chemotherapy. Fisetin is a bioactive flavonoid... 
ACUTE KIDNEY INJURY | OXIDATIVE STRESS | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | MITOCHONDRIAL DYSFUNCTION | PATHOLOGICAL ROLE | MECHANISMS | MICE | RENAL INJURY | CELL-DEATH | PROTECTS | Tumor Necrosis Factor-alpha - metabolism | Phosphorylation | Caspase 9 - genetics | Caspase 9 - metabolism | Kidney - pathology | Blood Urea Nitrogen | Tumor Necrosis Factor-alpha - genetics | Caspase 3 - metabolism | Male | Cytochromes c - genetics | I-kappa B Proteins - metabolism | I-kappa B Proteins - genetics | Transcription Factor RelA - genetics | Antineoplastic Agents - toxicity | Proto-Oncogene Proteins c-bcl-2 - metabolism | Kidney - metabolism | Cisplatin - toxicity | Caspase 3 - genetics | Flavonoids - pharmacology | Cisplatin - antagonists & inhibitors | NF-KappaB Inhibitor alpha | Kidney - drug effects | Signal Transduction | Cytochromes c - metabolism | Gene Expression Regulation | Rats | Antioxidants - pharmacology | Flavonoids - pharmacokinetics | Rats, Sprague-Dawley | Animals | Nitric Oxide Synthase Type II - genetics | Transcription Factor RelA - metabolism | Creatinine - blood | Peroxidase - genetics | Antioxidants - pharmacokinetics | Proto-Oncogene Proteins c-bcl-2 - genetics | Nitric Oxide Synthase Type II - metabolism | Peroxidase - metabolism | Cytochrome | Bcl-2 protein | Syngeneic grafts | C protein | Cytotoxicity | Cytosol | Caspase-3 | NAD(P)H oxidase | Antioxidants | Proteins | Elevation | Mitochondria | Enzymatic activity | Animal tissues | Bioindicators | Medical research | NF-κB protein | Committees | Gene expression | Studies | Cytochrome c | Urea | Chemistry | Chemotherapy | Flavonoids | Caspase-9 | Biomarkers | Kidney transplantation | Oxidative stress | Enzyme activity | Bax protein | Platinum | Rodents | CYBB protein | Peroxidase | Pharmaceutical sciences | Creatinine | Translocation | Antiinflammatory agents | Kidneys | Caspase | Inflammation | Pharmacology | Cisplatin | Acids | Apoptosis | Cancer | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 2015, Volume 26, Issue 8, pp. 1533 - 1546
The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast... 
Radiation therapy | Early breast cancer | St Gallen Consensus | Systemic adjuvant therapies | Surgery | early breast cancer | ADJUVANT CHEMOTHERAPY | ENDOCRINE THERAPY | PREMENOPAUSAL WOMEN | ESTROGEN-RECEPTOR | PATHOLOGICAL COMPLETE RESPONSE | TUMOR-INFILTRATING LYMPHOCYTES | OVARIAN-FUNCTION SUPPRESSION | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | radiation therapy | SENTINEL NODE | CONTRALATERAL PROPHYLACTIC MASTECTOMY | systemic adjuvant therapies | surgery | Carcinoma, Lobular - pathology | Receptors, Estrogen - metabolism | Humans | Carcinoma, Intraductal, Noninfiltrating - metabolism | Mastectomy - methods | Receptor, ErbB-2 - metabolism | Tamoxifen - administration & dosage | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Breast Neoplasms - therapy | Anthracyclines - administration & dosage | Carcinoma, Lobular - therapy | Carcinoma, Intraductal, Noninfiltrating - therapy | Antineoplastic Agents, Hormonal - therapeutic use | Axilla | Carcinoma, Ductal, Breast - pathology | Female | Carcinoma, Ductal, Breast - metabolism | Mastectomy, Segmental - methods | Trastuzumab - administration & dosage | Carcinoma, Ductal, Breast - therapy | Taxoids - administration & dosage | Carcinoma, Intraductal, Noninfiltrating - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Chemotherapy, Adjuvant - methods | Radiotherapy, Adjuvant - methods | Carcinoma, Lobular - metabolism | Platinum Compounds - administration & dosage | Lymph Node Excision - methods | Neoplasm Staging | Practice Guidelines as Topic | Special
Journal Article